180 related articles for article (PubMed ID: 9655890)
1. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
Graham MJ; Crooke ST; Monteith DK; Cooper SR; Lemonidis KM; Stecker KK; Martin MJ; Crooke RM
J Pharmacol Exp Ther; 1998 Jul; 286(1):447-58. PubMed ID: 9655890
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
5. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
7. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration.
Graham MJ; Crooke ST; Lemonidis KM; Gaus HJ; Templin MV; Crooke RM
Biochem Pharmacol; 2001 Aug; 62(3):297-306. PubMed ID: 11434902
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
[TBL] [Abstract][Full Text] [Related]
9. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.
Soucy NV; Riley JP; Templin MV; Geary R; de Peyster A; Levin AA
Birth Defects Res B Dev Reprod Toxicol; 2006 Feb; 77(1):22-8. PubMed ID: 16496297
[TBL] [Abstract][Full Text] [Related]
10. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler M; Stecker K; Bennett CF
Lab Invest; 1997 Oct; 77(4):379-88. PubMed ID: 9354772
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
Zhang R; Iyer RP; Yu D; Tan W; Zhang X; Lu Z; Zhao H; Agrawal S
J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755
[TBL] [Abstract][Full Text] [Related]
12. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type alpha1(I) collagen gene promoter in normal and fibrotic rats.
Cheng K; Ye Z; Guntaka RV; Mahato RI
Mol Pharm; 2005; 2(3):206-17. PubMed ID: 15934781
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of antisense oligonucleotides in rat liver homogenates.
Crooke RM; Graham MJ; Martin MJ; Lemonidis KM; Wyrzykiewiecz T; Cummins LL
J Pharmacol Exp Ther; 2000 Jan; 292(1):140-9. PubMed ID: 10604941
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.
Cossum PA; Truong L; Owens SR; Markham PM; Shea JP; Crooke ST
J Pharmacol Exp Ther; 1994 Apr; 269(1):89-94. PubMed ID: 8169856
[TBL] [Abstract][Full Text] [Related]
17. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
Phillips JA; Craig SJ; Bayley D; Christian RA; Geary R; Nicklin PL
Biochem Pharmacol; 1997 Sep; 54(6):657-68. PubMed ID: 9310342
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
